Imvax
Imvax is a clinical-stage biotechnology company focused on developing personalized, whole tumor-derived immunotherapies for solid tumors, including glioblastoma. Their lead platform, IGV-001, is an autologous tumor cell vaccine designed to induce a broad and durable immune response against tumors. The company is committed to revolutionizing immunotherapy and has a pipeline of clinical trials and research supporting their innovative approach.
Industries
Nr. of Employees
small (1-50)
Imvax
601 Walnut Street, Suite 440W, Philadelphia, PA 19106
Products
IGV‑001 (autologous tumor‑derived biologic‑device combination)
An autologous therapy comprising irradiated patient tumor cells combined with an antisense oligonucleotide, loaded into an implantable/removable biodiffusion chamber to release antigenic products and induce innate and adaptive immune responses against solid tumors; evaluated in Phase 1/1b and Phase 2b clinical studies for newly diagnosed glioblastoma.
Pipeline of personalized whole tumor‑derived investigational programs
A portfolio approach applying the same tumor‑derived biologic‑device methodology to multiple solid tumor indications (examples referenced in preclinical and pipeline materials include endometrial, ovarian, hepatocellular and other tumor types).
IGV‑001 (autologous tumor‑derived biologic‑device combination)
An autologous therapy comprising irradiated patient tumor cells combined with an antisense oligonucleotide, loaded into an implantable/removable biodiffusion chamber to release antigenic products and induce innate and adaptive immune responses against solid tumors; evaluated in Phase 1/1b and Phase 2b clinical studies for newly diagnosed glioblastoma.
Pipeline of personalized whole tumor‑derived investigational programs
A portfolio approach applying the same tumor‑derived biologic‑device methodology to multiple solid tumor indications (examples referenced in preclinical and pipeline materials include endometrial, ovarian, hepatocellular and other tumor types).
Services
GMP‑level cell processing center for manufacture of investigational and potential commercial supplies of autologous tumor‑derived therapies to support internal clinical programs.
Operational management and site coordination for multicenter randomized oncology trials, including enrollment, study drug/device administration logistics, and trial monitoring.
GMP‑level cell processing center for manufacture of investigational and potential commercial supplies of autologous tumor‑derived therapies to support internal clinical programs.
Operational management and site coordination for multicenter randomized oncology trials, including enrollment, study drug/device administration logistics, and trial monitoring.
Expertise Areas
- Personalized cancer immunotherapy
- Autologous cell therapy development
- Clinical trial design and execution (oncology)
- Translational immunology and mechanism-of-action studies
Key Technologies
- Autologous whole tumor‑cell vaccines
- Antisense oligonucleotide integration
- Implantable/removable biodiffusion chambers
- Immunogenic cell death assays
News & Updates
Imvax announced the completion of a $29 million financing round to support the Phase 2b trial of IGV-001 in glioblastoma, with topline results expected in mid-2025.
Imvax announced it will present safety data on IGV-001 at the 2024 Society for NeuroOncology Annual Meeting.
Imvax announced the dosing of the first patient in its Phase 2b trial of IGV-001 in glioblastoma patients.
Imvax reported that median overall survival was 21.9 months for the highest vaccine dose versus 14.6 months in published standard of care studies.
Imvax was recognized as one of the most promising private biotech companies in 2020 by Fierce Biotech.
The financing supports Phase 2 development of IGV-001 and expansion into other solid tumor indications.
Imvax announced the completion of a $29 million financing round to support the Phase 2b trial of IGV-001 in glioblastoma, with topline results expected in mid-2025.
Imvax announced it will present safety data on IGV-001 at the 2024 Society for NeuroOncology Annual Meeting.
Imvax announced the dosing of the first patient in its Phase 2b trial of IGV-001 in glioblastoma patients.
Imvax reported that median overall survival was 21.9 months for the highest vaccine dose versus 14.6 months in published standard of care studies.
Imvax was recognized as one of the most promising private biotech companies in 2020 by Fierce Biotech.
The financing supports Phase 2 development of IGV-001 and expansion into other solid tumor indications.